Paolo Tarantino: Adding palbociclib to fulvestrant did not improve PFS in the PACE randomized phase 2 trial

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Out in JCO, the PACE randomized phase 2 trial by Erica Mayer, Sara Tolaney et al. Among pts with HR+ MBC and prior progression on CDK4/6i (90% palbo), adding palbo to fulvestrant did not improve PFS (4.6 vs 4.8 mo). Interesting signal with fulv/palbo/avelumab.”